P-12 is under clinical development by NeoMatrix Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect P-12’s likelihood of approval (LoA) and phase transition for Burns took place on 12 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their P-12 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
P-12 is under development for the prevention and treatment of burns. It is a fibrinoectin derived bioactive peptide applied intravenously. It targets platelet-derived growth factor-BB (PDGF-BB).
NeoMatrix Therapeutics overview
NeoMatrix Therapeutics is a clinical-stage company that develops novel therapeutic agents for the treatment of serious burn injuries and focus on the treatment of severe burns. NeoMatrix Therapeutics is headquartered in Suffolk County, New York, the US.
Quick View P-12 LOA Data
|Highest Development Stage|